Athena Gold Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 1

Market Cap: $126.8M

Website: http://www.athira.com

Introduction: Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Clinical Trials

A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: ATH-1105
Drug: Placebo

First Posted Date: 2024-05-29

Last Posted Date: 2024-05-29

Lead Sponsor: Athira Pharma

Target Recruit Count: 80

Registration Number: NCT06432647

Locations: 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-Fosgonimeton

First Posted Date: 2022-08-23

Last Posted Date: 2022-12-22

Lead Sponsor: Athira Pharma

Target Recruit Count: 8

Registration Number: NCT05511558

Locations: 🇺🇸
Labcorp Clinical Research Unit, Madison, Wisconsin, United States

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ATH-1020
Drug: Placebo

First Posted Date: 2021-12-27

Last Posted Date: 2024-04-08

Lead Sponsor: Athira Pharma

Target Recruit Count: 32

Registration Number: NCT05169671

Locations: 🇺🇸
Biotrial, Inc., Newark, New Jersey, United States

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: ATH-1017

First Posted Date: 2021-05-13

Last Posted Date: 2024-11-15

Lead Sponsor: Athira Pharma

Target Recruit Count: 423

Registration Number: NCT04886063

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States

and more 70 locations

ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)

Phase 2

Completed

Conditions: Parkinson Disease Dementia
Dementia With Lewy Bodies

Interventions: Drug: ATH-1017
Drug: Placebo

First Posted Date: 2021-04-05

Last Posted Date: 2024-04-15

Lead Sponsor: Athira Pharma

Target Recruit Count: 28

Registration Number: NCT04831281

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸
QUEST Research Institute, Farmington Hills, Michigan, United States

and more 7 locations

A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease
Dementia of Alzheimer Type

Interventions: Drug: ATH-1017
Drug: Placebo

First Posted Date: 2020-07-29

Last Posted Date: 2023-06-12

Lead Sponsor: Athira Pharma

Target Recruit Count: 77

Registration Number: NCT04491006

Locations: 🇺🇸
Premiere Research Institute, West Palm Beach, Florida, United States
🇺🇸
Neurological Associates of Albany, Albany, New York, United States
🇦🇺
Australian Alzheimer's Research Organization, Nedlands, Western Australia, Australia

and more 10 locations

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer Disease
Dementia of Alzheimer Type

Interventions: Drug: ATH-1017
Drug: Placebo

First Posted Date: 2020-07-28

Last Posted Date: 2024-11-15

Lead Sponsor: Athira Pharma

Target Recruit Count: 554

Registration Number: NCT04488419

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Xenoscience, Phoenix, Arizona, United States
🇺🇸
Banner Sun Health Research Institute, Sun City, Arizona, United States

and more 83 locations

Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: NDX-1017
Drug: Placebo

First Posted Date: 2017-10-02

Last Posted Date: 2019-09-10

Lead Sponsor: Athira Pharma

Target Recruit Count: 88

Registration Number: NCT03298672

Locations: 🇺🇸
Biotrial Inc., Newark, New Jersey, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy